{
    "Trade/Device Name(s)": [
        "ONLINE TDM Procainamide"
    ],
    "Submitter Information": "Roche Diagnostics Corporation",
    "510(k) Number": "K060773",
    "Predicate Device Reference 510(k) Number(s)": [
        "K951595"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LAR"
    ],
    "Summary Letter Date": "August 23, 2006",
    "Summary Letter Received Date": "July 28, 2006",
    "Submission Date": "July 27, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.3320"
    ],
    "Regulation Name(s)": [
        "Digoxin test system"
    ],
    "Analyte Class(es)": [
        "tdm",
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "Procainamide"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche Hitachi 911",
        "Roche Hitachi 912",
        "Roche Hitachi 917",
        "Modular P analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay",
        "Spectrophotometric detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Roche ONLINE TDM Procainamide homogeneous enzyme immunoassay for quantitative determination of procainamide in serum or plasma",
    "Indications for Use Summary": "Quantitative determination of procainamide in human serum or plasma for diagnosis and treatment of procainamide overdose and monitoring therapeutic levels using Roche automated clinical chemistry analyzers",
    "fda_folder": "Toxicology"
}